Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Affimed halts trial after patient death and SAEs

Following the announcement, Affimed's stocks dropped by 30%. Affimed's tetravalent bispecific antibody-generating ROCK platform was a main...

Investors pool €27m for new Proteomics tech

Developed at the University of Cambridge, Fluidic Analytics’ platform is designed to give insights into the way that proteins fold, aggregate and...

Dry AMD: Oxurion licences heparanase blockers from Beta Therapeutics

Under the terms of the agreement Oxurion will have an exclusive option to license the heparanase inhibitor programmes developed for the...

Breakthrough in restless legs syndrome

According to Dirk Czesni, "the mechanisms for Restless Legs Syndrome are still not completely understood. "We have shown that the...

Sitryx Therapeutics bags $30m in Series A Financing

The company is closely linked to GSK and will have the opportunity to use the drugmaker's resources. Sitryx Therapeutics has been spun-off this year...

British F2G Biotech bags €24m

F2G Biotech said it will be spending most of the assets to push forward pivotal clinical trials of its lead compound Olorofim (F901318), a Phase IIb...

CAR-Ts: Novartis wins UK

The European Commission approved Kymriah last week for the treatment of children with the rare blood cancer ALL as well as for adults with refractory...